Literature DB >> 23123126

Unexplained extreme hyperbilirubinemia among neonates in a multihospital healthcare system.

Robert D Christensen1, Diane K Lambert, Erick Henry, Larry D Eggert, Hassan M Yaish, N Scott Reading, Josef T Prchal.   

Abstract

We report a series of neonates who developed a total serum bilirubin (TSB) >20mg/dL during a recent ten-year period in a multihospital healthcare system. The incidence of a TSB >20mg/dL fell after instituting a pre-hospital discharge bilirubin screening program in 2003/2004 (91.3 cases/10,000 births before vs. 72.4/10,000 after), but the incidence has subsequently remained unchanged. No specific cause for the hyperbilirubinemia was identified in 66% of (n=32) cases with a TSB >30 mg/dL or in 76% of (n=112) cases with a TSB 25.0-29.9 mg/dL. We hypothesized that hemolysis was a common contributing mechanism, but our review of hospital records indicated that in most instances these infants were not evaluated sufficiently to test this hypothesis. Records review showed maternal and neonatal blood types and direct antiglobulin testing were performed in >95% cases, but rarely were other tests for hemolysis obtained. In the ten-year period reviewed there were zero instances where erythrocyte morphology from a blood film examination or Heinz body evaluation by a pediatric hematologist or pathologist were performed. In 3% of cases pyruvate kinase was tested, 3% were evaluated by hemoglobin electrophoresis, 3% had a haptoglobin measurement, and 16% were tested for G6PD deficiency. Thus, determining the cause for hyperbilirubinemia in neonates remains a problem at Intermountain Healthcare and, we submit, elsewhere. As a result, the majority of infants with a TSB >25mg/dL have no specific causation identified. We speculate that most of these cases involve hemolysis and that the etiology could be identified if searched for more systematically. With this in mind, we propose a "consistent approach" to evaluating the cause(s) of hyperbilirubinemia among neonates with a TSB >25mg/dL.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23123126     DOI: 10.1016/j.bcmd.2012.10.004

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  10 in total

1.  Causes of hemolysis in neonates with extreme hyperbilirubinemia.

Authors:  R D Christensen; R H Nussenzveig; H M Yaish; E Henry; L D Eggert; A M Agarwal
Journal:  J Perinatol       Date:  2014-04-24       Impact factor: 2.521

Review 2.  A pediatrician's practical guide to diagnosing and treating hereditary spherocytosis in neonates.

Authors:  Robert D Christensen; Hassan M Yaish; Patrick G Gallagher
Journal:  Pediatrics       Date:  2015-06       Impact factor: 7.124

3.  HIF-mediated increased ROS from reduced mitophagy and decreased catalase causes neocytolysis.

Authors:  Jihyun Song; Donghoon Yoon; Robert D Christensen; Monika Horvathova; Perumal Thiagarajan; Josef T Prchal
Journal:  J Mol Med (Berl)       Date:  2015-05-28       Impact factor: 4.599

4.  Report about term infants with severe hyperbilirubinemia undergoing exchange transfusion in Southwestern China during an 11-year period, from 2001 to 2011.

Authors:  Canfeng Yu; Huifan Li; Qiannan Zhang; Huayun He; Xinhong Chen; Ziyu Hua
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

Review 5.  How Do Red Blood Cells Die?

Authors:  Perumal Thiagarajan; Charles J Parker; Josef T Prchal
Journal:  Front Physiol       Date:  2021-03-15       Impact factor: 4.566

6.  Novel SPTB frameshift mutation in a Chinese neonatal case of hereditary spherocytosis type 2: A case report.

Authors:  Cunxin Xu; Ya Wu; Dujuan Wang; Xuemin Zhang; Ningling Wang
Journal:  Exp Ther Med       Date:  2022-07-28       Impact factor: 2.751

7.  International guidelines regarding the role of IVIG in the management of Rh- and ABO-mediated haemolytic disease of the newborn.

Authors:  Lani Lieberman; Enrico Lopriore; Jillian M Baker; Rachel S Bercovitz; Robert D Christensen; Gemma Crighton; Meghan Delaney; Ruchika Goel; Jeanne E Hendrickson; Amy Keir; Denise Landry; Ursula La Rocca; Brigitte Lemyre; Rolf F Maier; Eduardo Muniz-Diaz; Susan Nahirniak; Helen V New; Katerina Pavenski; Maria Cristina Pessoa Dos Santos; Glenn Ramsey; Nadine Shehata
Journal:  Br J Haematol       Date:  2022-04-12       Impact factor: 8.615

Review 8.  Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels.

Authors:  Vinod K Bhutani; Alvin Zipursky; Hannah Blencowe; Rajesh Khanna; Michael Sgro; Finn Ebbesen; Jennifer Bell; Rintaro Mori; Tina M Slusher; Nahed Fahmy; Vinod K Paul; Lizhong Du; Angela A Okolo; Maria-Fernanda de Almeida; Bolajoko O Olusanya; Praveen Kumar; Simon Cousens; Joy E Lawn
Journal:  Pediatr Res       Date:  2013-12       Impact factor: 3.756

9.  Burden of severe neonatal jaundice: a systematic review and meta-analysis.

Authors:  Tina M Slusher; Tara G Zamora; Duke Appiah; Judith U Stanke; Mark A Strand; Burton W Lee; Shane B Richardson; Elizabeth M Keating; Ashajoythi M Siddappa; Bolajoko O Olusanya
Journal:  BMJ Paediatr Open       Date:  2017-11-25

10.  UGT1A1 mutation association with increased bilirubin levels and severity of unconjugated hyperbilirubinemia in ABO incompatible newborns of China.

Authors:  Hui Yang; Fen Lin; Zi-Kai Chen; Lin Zhang; Jia-Xin Xu; Yong-Hao Wu; Jing-Ying Gu; Yu-Bin Ma; Jian-Dong Li; Li-Ye Yang
Journal:  BMC Pediatr       Date:  2021-06-01       Impact factor: 2.125

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.